- project . 2019 - 2023Funder: EC Project Code: 861278Overall Budget: 1,292,900 EURFunder Contribution: 1,292,900 EUROpen Access mandate for PublicationsPartners: TU Dortmund University, JANSSEN PHARMACEUTICA NV, UL
LongActNow will design a novel platform technology for the development of long acting (LA) suspensions of complex active pharmaceutical ingredients (API), involving innovative manipulation of API crystal formation and growth and solvent removal. LA formulations have bec...
- project . 2017 - 2021Funder: EC Project Code: 683144Overall Budget: 1,997,920 EURFunder Contribution: 1,997,920 EUROpen Access mandate for PublicationsPartners: Ghent University, VLAAMS INSTITUUT BIOTECHNOLOGIE FLANDERS INSTITUTE FOR BIOTECHNOLOGY, JANSSEN PHARMACEUTICA NV
Programmed cell death is essential for homeostasis, and its deregulation contributes to human disease. Inflammasome-induced pyroptosis of infected macrophages contributes to host defense against infections, but the concomitant release of inflammatory danger signals and ...
- project . 2018 - 2020Funder: EC Project Code: 820588Overall Budget: 2,935,000 EURFunder Contribution: 2,054,500 EUROpen Access mandate for PublicationsPartners: JANSSEN PHARMACEUTICA NV, PDS PATHOLOGY DATA SYSTEMS AG, DECIPHEX LIMITED
Drug discovery is a time consuming, expensive and risky process. Each drug to market must undergo safety/ toxicity testing in animals which yields thousands of tissue sections that currently must be assessed manually by a trained veterinary pathology. However, there is ...
- project . 2014 - 2020Funder: EC Project Code: 115847Overall Budget: 20,402,800 EURFunder Contribution: 20,328,900 EUROpen Access mandate for PublicationsPartners: WORLD VISION OF IRELAND, LSHTM, Grameen Foundation, JANSSEN PHARMACEUTICA NV
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment. The EBODAC consortium consists of 4 partners: Janssen (EFPIA), London School of Hygiene and Tropical Medicine (LSHTM), World Vision of Ireland and Grameen Foundation . These part...
- project . 2015 - 2019Funder: EC Project Code: 676144Overall Budget: 3,846,740 EURFunder Contribution: 3,846,740 EUROpen Access mandate for PublicationsPartners: UMIL, UNIVERSITE DE BORDEAUX, AXON NEUROSCIENCE SE, DZNE, JANSSEN PHARMACEUTICA NV, Karolinska Institutet Innovations (Sweden)
Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programm...
organization